Transgene and BioInvent Announce a Poster Presentation on BT-001, a Novel Oncolytic Virus Encoding Antibodies, at AACR 2022

Preclinical Data Shows Robust Anti-tumor Activity of BT-001, Including Its Highly Effective and Safe CTLA-4 Targeting Therapeutic Strategy

STRASBOURG, France & LUND, Sweden, March 09, 2022–(BUSINESS WIRE)–Regulatory news:

Transgene (Euronext Paris: TNG)a biotechnology company that designs and develops viral immunotherapies against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotechnology company focused on the discovery and development of novel and innovative immunomodulatory antibodies for cancer immunotherapy, today jointly announce that an abstract reporting preclinical studies on BT-001, a novel oncolytic virus, has been selected for poster presentation at the 2022 Annual Meeting of the American Association for Cancer Research (AACR). The conference will be held in person in New Orleans, LA, April 8-13, 2022.

The poster will highlight that BT-001, a co-developed clinical-stage product based on Transgene’s proprietary oncolytic vector and encoding BioInvent’s proprietary anti-CTLA-4 antibody, has the potential to provide superior therapeutic benefit to systemically administered anti-CTLA-4 antibodies.

The preclinical data that will be presented demonstrate that vectorized anti-CTLA-4 antibodies delivered intratumorally (it) can improve safety by reducing their systemic exposure. Efficacy can also be improved, with evidence from the immunocompetent mouse model showing that vectored anti-CTLA-4 antibodies have anti-tumor activity even against “cold tumors” that are resistant to intravenously administered checkpoint inhibitors. systemic.

Additionally, the precise targeting of the antibody to a unique functional epitope of CTLA-4 provides a higher level of regulatory T cell (Treg) depletion than currently available immune checkpoint (ICB) blocking therapies.

The studies also provide several key insights into the likely mechanisms underlying BT-001’s effectiveness. Vectorized anti-CTLA-4:

  • triggered both Fcγ receptor-dependent Treg depletion and antigen cross-presentation – mechanisms known to trigger and promote long-lasting systemic CD8+ T-cell antitumor immunity;

  • showed broad antitumor activity, including activity against mouse models of “cold tumors” that are resistant to systemic checkpoint inhibitors;

  • showed additive or synergistic antitumor activity when combined with an anti-PD-1.

Details of the poster presentation are as follows:

Abstract Title: Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF.
Authors: Jean-Baptiste Marchand, Monika Semmrich, Christelle Remy, Matilda Rehn, Laetitia Fend, Petra Holmkvist, Nathalie Silvestre, Carolin Svensson, Patricia Kleinpeter, Jules Deforges, Fred Junghus, Linda Mårtensson, Johann Foloppe, Ingrid Teige, Björn Frendéus, Éric Quéméneur.

Session category: Immunology
Session title: Vaccines: Oncolytics and Prophylactics
Session date and time: Tuesday, April 12, 2022, 1:30 p.m. – 5:00 p.m.
Location: New Orleans Convention Center, Exhibit Halls DH, Poster Section 40
Billboard number: 17
abstract number: 3567

The summary can be viewed on the AACR Annual Meeting website: https://www.aacr.org/meeting/aacr-annual-meeting-2022/.

***

About BT-001

BT-001 is an oncolytic virus generated using Transgene’s Invir.IO™ platform and its patented high capacity VVcopTK-RR-oncolytic virus, which was engineered to encode both a Treg-depleting recombinant human anti-CTLA-4 antibody generated by BioInvent’s proprietary n-CoDeR®/FIRST™ and the human cytokine GM-CSF. By selectively targeting the tumor microenvironment, BT-001 should elicit a much stronger and more effective antitumor response. Accordingly, by reducing systemic exposure, the safety and tolerability profile of the anti-CTLA-4 antibody will be greatly improved.

BT-001 is currently in a Phase I/IIa clinical study (NCT04725331) and recruitment is progressing steadily. The trial is evaluating BT-001 as a single agent and in combination with the PD-1 checkpoint inhibitor pembrolizumab against solid tumors. The first phase I data are expected in the first half of 2022.

BT-001 is co-developed as part of a 50/50 collaboration on oncolytic viruses between Transgene and BioInvent. To learn more about BT-001, watch our video here.

About Transgene

Transgene (Euronext: TNG) is a biotechnology company specializing in the design and development of targeted immunotherapies for the treatment of cancer. Transgene’s programs use viral vector technology to indirectly or directly kill cancer cells.

The Company’s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers and TG4050, the first individualized therapeutic vaccine based on the monvac®) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors and BT-001, the first oncolytic virus based on the Invir.IO™ platform).

With Transgene monvac®, therapeutic vaccination enters the field of precision medicine with a new immunotherapy fully adapted to each individual. the monvac® enables the generation of virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.

With its proprietary Invir.IO™ platform, Transgene relies on its expertise in viral vector engineering to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO™ collaboration with AstraZeneca.

Additional information on Transgene is available at: www.transgene.fr.

Follow us on twitter: @TransgeneSA

About BioInvent

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotechnology company discovering and developing first-in-class novel immunomodulatory antibodies for the treatment of cancer, with currently three drug candidates in four ongoing clinical programs in phase l/ ll trials for the treatment of hematological cancer and solid tumors, respectively. The company’s validated and proprietary FIRST™ technology platform simultaneously identifies targets and the antibodies that bind to them, generating many promising new drug candidates to feed into the company’s own clinical development pipeline or for in-licensing and additional partnerships.

The Company generates revenue from research collaborations and licensing agreements with several leading pharmaceutical companies, as well as antibody production for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com.

Follow us on twitter: @BioInvent

Transgene Disclaimer

This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of one of these risks could have a significant negative impact on the Company’s activities, prospects, financial situation, results, approval of the regulatory authorities on the development phases and development. The Company’s ability to market its products depends, but is not limited to, the following factors: positive preclinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/ or partnerships for product manufacturing, development and marketing, and marketing approval by governmental regulatory authorities. For a discussion of the risks and uncertainties that could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors section (” Risk factors”) of the Universal Registration Document, available on the AMF website (http://www.amf-france.org) or on the Transgene website (www.transgene.fr). Forward-looking statements speak only as of the date they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Disclaimer of BioInvent

The press release contains forward-looking statements, consisting of subjective assumptions and forecasts of future scenarios. Predictions about the future speak only as of the date on which they are made and are, by their very nature, like research and development in the field of biotechnology, associated with risks and uncertainties. . With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220308006144/en/

contacts

Transgene:
Jean-Philippe Del
Financial director
+33 (0)3 88 27 91 00
[email protected]

Media: MEDISTRAVA Consulting
David Dible/Sylvie Berrebi
+44 (0)7714 306525
[email protected]

BioInvent:
Cecilia Hofvander
Senior Director of Investor Relations
+46 (0)46 286 85 50
[email protected]

BioInvent International AB (publisher):
Co. Reg. Org No.: 556537-7263
Visiting address: Ideongatan 1
Postal address: 223 70 LUND
Telephone: +46 (0)46 286 85 50
www.bioinvent.com

Comments are closed.